FDA NOTE TO CORRESPONDENTS

FDA NOTE TO CORRESPONDENTS
For Immediate Release: Oct. 2, 2009

Media Inquiries: Raymond Formanek Jr., 301-796-4677; [email protected]
Other Inquiries: Afia Asamoah, 301-796-4625; [email protected]

FDA Transparency Task Force to Hold 2nd Public Meeting on Ensuring That Agency Information is Useful, Understandable, Accessible
The U.S. Food and Drug Administration will seek comments on how to ensure that information on FDA activities and decision-making is useful, understandable, and accessible to the public, during a daylong public meeting on Nov. 3, 2009.

The meeting is scheduled for 9 a.m. to 3 p.m. at the National Transportation Safety Board Conference Center, 429 L'Enfant Plaza, S.W., Washington, D.C., 20594.
The purpose of the meeting is to receive detailed comments on three specific issues related to transparency at the FDA:

Early communication about emerging safety issues concerning FDA-regulated products
Disclosure of information about product applications that are abandoned, i.e., no work is being done or will be undertaken to have the application approved, or withdrawn by the applicant before approval
Communication of agency decisions about pending product applications.
The FDA formed an internal Transparency Task Force in response to the Obama Administration's commitment to achieve "an unprecedented level of openness in Government." The Task Force is developing recommendations for making useful and understandable information about FDA activities and decision-making more readily available to the public in a timely manner and in a user-friendly format, while appropriately protecting confidential information.

The task force held its first daylong meeting in June 2009.

Those interested in attending the public meeting must register by 5 p.m. on Oct. 27, 2009. Submit electronic or written comments by Nov. 6, 2009. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852.

There is no fee to register for the meeting and registration is on a first-come, first-served basis. Seating is limited and early registration is recommended. Registration on the day of the public meeting will be permitted on a space-available basis, beginning at 7:30 a.m.

A media room with dial-up Internet access will be provided. Please note there is no wireless service within the NTSB Conference Center. Those who cannot attend the meeting can view it via live Webcast.

The Webcast will be archived and available for viewing on the FDA Web site.

For more information:
Advance Display of Federal Register Notice to publish Oct. 5, 2009
http://www.federalregister.gov/OFRUpload/OFRData/2009-23916_PI.pdf

FDA Transparency Task Force
http://www.fda.gov/AboutFDA/WhatWeDo/FDATransparencyTaskForce/default.htm

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.